Current Report Filing (8-k)
December 02 2016 - 4:31PM
Edgar (US Regulatory)
SECURITIES
AND EXCHANGE COMMISSION
WASHINGTON,
D.C. 20549
FORM
8-K
CURRENT
REPORT
PURSUANT
TO SECTION 13 OR 15(d) OF
THE
SECURITIES EXCHANGE ACT OF 1934
Date of Report (Date of earliest event reported): November 30, 2016
OptimizeRx Corporation
(Exact name of registrant as specified in its charter)
Nevada
|
|
000-53605
|
|
26-1265381
|
(State
or other jurisdiction
of incorporation)
|
|
(Commission
File Number)
|
|
(I.R.S.
Employer
Identification No.)
|
400
Water Street, Suite 200, Rochester, MI
|
|
48307
|
(Address
of principal executive offices)
|
|
(Zip
Code)
|
Registrant’s
telephone number, including area code:
248.651.6568
(Former name or former address, if changed
since last report)
Check
the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant
under any of the following provisions:
☐
|
Written
communications pursuant to Rule 425 under the Securities Act (17CFR 230.425)
|
|
|
☐
|
Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
|
|
☐
|
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
|
|
☐
|
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
SECTION
5 – CORPORATE GOVERNANCE AND MANAGEMENT
Item
5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements
of Certain Officers
On
November 30, 2016, Mr. James Brooks moved to a consulting role with our company. Effective on that date, Mr. Brooks will no longer
serve as our Senior Vice President of Business Development. We agreed to pay all compensation and reimbursable expenses through
December 31, 2016. Mr. Brooks has also provided us a release of all claims in connection with the end of his employment relationship
and move to his consulting role.
Commencing
January 1, 2017, Mr. Brooks will serve as a consultant for one year and assist with our selling efforts to EHRs. For his consulting,
we have agreed to compensate him a fee for each signed and integrated EHR plus a percentage of the net revenues received from
such EHRs during his consulting period. Special projects will be billed to us at an hourly rate.
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf
by the undersigned hereunto duly authorized.
OptimizeRx
Corporation
Douglas
Baker
Chief Financial Officer
Date:
December 2, 2016
3
OptimizeRx (NASDAQ:OPRX)
Historical Stock Chart
From Mar 2024 to Apr 2024
OptimizeRx (NASDAQ:OPRX)
Historical Stock Chart
From Apr 2023 to Apr 2024